Eradication of Borrelia Burgdoferi in vitro using Chlorine Dioxide: A Novel Approach
Main Article Content
Lyme disease, which is caused by the spirochete Borrelia burgdorferi is the most prevalent tick-borne illness in the world today and has grown into a major public health problem during the last decade, irrelevant to decades of efforts from various health professionals.
The conventional treatment for Lyme disease is the use of a variety of antibiotics, but relapse often occurs when antibiotics are discontinued. There are several reasons why this relapse may occur, given that B. burgdorferi is a pleomorphic microorganism that can convert from vegetative spirochetes to a variety of different round bodies and biofilm colonies. Therefore, there is an urgent need for novel approaches that can eliminate all these different morphologies.
This has challenged many health practitioners around the world, not to mention the suffering of many afflicted people. In this study, Chlorine dioxide (CD) at different concentrations was tested for its effectiveness in vitro against B. burgdorferi using combined fluorescent and darkfield microscopy with Live-or-Dye staining methods. Our experiments demonstrated that it is possible to completely eradicate all forms of B. burgdorferi at specific concentrations of Chlorine dioxide. Our extensive research has shown that Chlorine dioxide can be used for the eradication of B. burgdorferi morphologies.
At certain concentrations of chlorine dioxide above 2 ppm the Borrelia morphologies appear to be eradicated as there is no motility of either spirochetes or round bodies, only biofilms visible. However, incubating again for another 7 days resulted in the Borrelia being motile again as they come out of the biofilms.
We, therefore, decided to conduct each experiment with what we termed the Regrowth Kill Test (RKT) by incubating the initial sample with the CD in an incubator at 37 degrees centigrade in the Campypack for 7-days. It appeared that the biofilms that are quickly formed as soon as the CD is added in the initial experiment, broke up and released small spirochetes and round bodies of different morphologies.
After numerous RKT experiments, it was determined that the concentration that resulted in a near complete disinfection of the spirochetes as well as round bodies was 30 ppm CD.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2. Stricker RB, Johnson L. Lyme disease diagnosis and treatment: lessons from the AIDS epidemic. Minerva Med. 2010;101(6):419–425. [PubMed] [Google Scholar]
3. Radolf JD, Caimano MJ, Stevenson B. Hu LT. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev Microbiol. 2012. 10, 87–99.
4. Mead PS. Global epidemiology of Borrelia burgdorferi infections. In Lyme Disease: An Evidence-based Approach, 2011. pp. 110–114. Edited by J. J. Halperin. Wallingford: CAB International.
5. Kugeler K, Schwartz A, Delorey M, Mead P, Hinckley A. Estimating the frequency of Lyme disease diagnoses, United States, 2010–2018. Emerg Infect Dis J. 2021. 27:616–9. doi: 10.3201/eid2702.202731.
6. Schotthoefer AM, Frost HM. Ecology and epidemiology of Lyme borreliosis. Clin. Lab. Med. 2015, 35, 723–743.
7. Rosenberg R, Lindsey NP, Fischer M, Gregory CJ, Hinckley AF, Mead PS, Paz‐Bailey G, Waterman SH, Drexler NA, Kersh GJ et al. Vital signs: Trends in reported vectorborne disease cases - United States and Territories, 2004‐2016. Morb. Mortal. Wkly. Rep. 2018, 67, 496–501.
8. Adrion ER, Aucott J, Lemke KW, Weiner JP. Health care costs, utilization and patterns of care following Lyme disease. PLoS ONE. 2015. 10:e0116767. doi: 10.1371/journal.pone.0116767.
9. Adrion ER, Aucott J, Lemke KW, Weiner JP. Health Care Costs, Utilization and Patterns of Care following Lyme Disease. PLOS ONE. 2015. 10(2): e0116767. https://doi.org/10.1371/journal.pone.0116767
10. Goodlet KJ, Fairman KA. Adverse events associated with antibiotics and intravenous therapies for post-Lyme disease syndrome in a commercially insured sample.external icon Clin Infect Dis. 2018 Oct 30;67(10):1568-1574.
11. De Wilde M, Speeckaert M, Callens R, Van Biesen W. Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of ‘chronic Lyme disease’. external icon Acta Clin Belg. 2017 Apr;72(2):133-137.
12. Klempner MS, Linden MD, Hu T, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall, D, McCall, J, Kosinski, M, Weinstein, A. Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease. N Engl J Med Jul 2001; 345:85-92. DOI: 10.1056/NEJM200107123450202.
13. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, Dattwyler R, Chandler B. Study and treatment of post Lyme disease (STOP-LD): a randomized double-masked clinical trial. Neurology. 2003 Jun 24;60(12):1923-30. doi: 10.1212/01.wnl.0000071227.23769.9e.
14. Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT, Evans J, Weinstein A, Schmid CH, Klempner MS. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology. 2003 Jun 24;60(12):1916-22. doi: 10.1212/01.wnl.0000068030.26992.25.
15. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008 Mar 25;70(13):992-1003. doi: 10.1212/01.WNL.0000284604.61160.2d. Epub 2007 Oct 10.
16. Mattman LH. Cell Wall Deficient Forms – Stealth Pathogens, 3rd edn. 2001. Boca Raton, FL: CRC Press.
17. Berndtson K. Review of evidence or immune evasion and persistent infection in Lyme disease. Int J Gen Med 6, 2013. 291–306.
18. Domingue GJ, Woody, HB. Bacterial persistence and expression of disease. Clin Microbiol Rev 10, 1997. 320–344.
19. Glover WA., Yang Y, Zhang Y. Insights into the molecular basis of L-form formation and survival in Escherichia coli. PLoS ONE 4, 2009. e7316.
20.Ranjit DK, Young KD. The Rcs stress response and accessory envelope proteins are required for de novo generation of cell shape in Escherichia coli. J Bacteriol 195, 2013. 2452–2462
21. Briers Y, Staubli T, Schmid MC, Wagner M, Schuppler M, Loessner MJ. Intracellular vesicles as reproduction elements in cell wall-deficient L-form bacteria. PLoS ONE 7, 2012. e38514.
22. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol 8, 2010. 623–633.
23. Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, Pabbati N, Poruri A, Burugu D, Theophilus PAS, et al. Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLoS ONE 7, 2012. e48277.
24. Srivastava SY, de Silva AM. Characterization of Borrelia burgdorferi aggregates. Vector-Borne Zoonotic Dis 9, 2009. 323–329.
25. Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, Pabbati N, Poruri A, Burugu D, Theophilus PAS, Pham TV, et al. Characterization of Biofilm Formation by Borrelia burgdorferi In Vitro. PLoS One 2012, 7, 1–11.
26. Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J. Neuroinflammation 2008, 5, 1–18.
27. Meriläinen L, Herranen A, Schwarzbach A, Gilbert L. Morphological and biochemical features of Borrelia burgdorferi pleomorphic forms. Microbiol. (United Kingdom) 2015, 161, 516–527.
28. Vancová M, Rudenko N, Vaněček J, Golovchenko M, Strnad M, Rego ROM, Tichá L, Grubhoffer L, Nebesářová J. Pleomorphism and viability of the Lyme disease pathogen Borrelia burgdorferi exposed to physiological stress conditions: A correlative cryo‐fluorescence and cryo‐scanning electron microscopy study. Front. Microbiol. 2017, 8, 1–9.
29. Brorson O, Brorson S.H. In vitro conversion of Borrelia burgdorferi to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK‐H medium. Infection 1998, 26, 144–150.
30. Brorson I, Brorson S.H. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine. Int. Microbiol. 2002, 5, 25–31.
31. Murgia R, Cinco M. Induction of cystic forms by different stress conditions in Borrelia burgdorferi. APMIS 2004, 112, 57–62.
32. Mursic VP, Wanner G, Reinhardt S, Busch U, Maget W. Formation and cultivation of Borrelia burgdorferi spheroblast‐L‐form variants. Infection 1996, 24, 218–226.
33. Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W. Heterogeneity of Borrelia burgdorferi in the Skin. Am. J. Dermatopathol. 1996, 18, 571–579.
34. Rudenko N, Golovchenko M, Kybicova K, Vancová M. Metamorphoses of Lyme disease spirochetes: phenomenon of Borrelia persisters. Parasit. Vectors 2019, 12, 1–10.
35. Caccammo PD, Brun YV. The Molecular Basis of Noncanonical Bacterial Morphology. Trends Microbiol 2018, 26, 191–208.
36. Justice, SS Hunstad DA, Cegelski L, Hultgren SJ. Morphological plasticity as a bacterial survival strategy. Nat Rev Microbiol 2008, 6, 162–168.
37. Domingue GJ, Woody, HB. Bacterial persistence and expression of disease. Clin. Microbiol. Rev. 1997, 10, 320–344.
38. Reference for CDSPlus - https://aquarius-prolife.com
39. Simpson GD, Miller RF, Laxton GD, Clements WR. A focus on chlorine dioxide: the "ideal" biocide. Corrosion 93. New Orleans, La, March 1993. 8-12 paper No. 472.. Available: http://www.clo2.gr/en/pdf/secure/chlorinedioxideidealbiocide.pdf. Accessed 2013 April 15. [Google Scholar]
40. Nelson TR. "Appleton Papers Finds Chlorine Dioxide to be an Alternative to Conventional Biocides in Alkaline Systems," TAPPI J., 65(6), 69 (1982). 35. T. R. Nelson, "Chlorine Dioxide: An Alternative to Conventional Biocides in Alkaline Systems," paper presented at the Annul. Meet. ‐ Tech. Assoc. Pulp Pap. Ind., 261 (1982). 36. E. R. Balcer, "Using Chlorine Dioxide for Slime Control in Alkcaline Paper Machine Systems," TAPPI J., 64"8), 91 (1981). 37. E. R. Baker, "Chlorine Dioxide Proves an Effective Biocide in Alkaline Whitewater Systems," Pulp Pap., 54(8), 140 (1980).
41. MacDonald AB. Spirochetal cyst forms in neurodegenerative disorders,... hiding in plain sight. Med. Pathogens 2019, 8, 299 56 of 57 Hypotheses 2006, 67, 819–832.
42. Margulis L, Maniotis A, MacAllister J, Scythes J, Brorson O, Hall J, Krumbein WE, Chanman MJ. Spirochete round bodies syphilis, lyme disease & AIDS: Resurgence of “the great imitator”? Symbiosis 2009, 47, 51–58.
43. Synan JF. "Chlorine Dioxide ‐ An Effective Biocide for Recycled or Reused Water Systems," Trans. Citrus Eng. Conf., 1979. 25, 66.
44. Welch JL, Folinazzo JF. "Use of Chlorine Dioxide for Cannery Sanitation and Water Conservation," Food Tech., 1958. March, 179.
45. Sussrnan S, Ward WJ. "Chlorine Dioxide is an Attractive Treatment Alternative," W&SW, 1979. 120.
46. Sussman S, Ward WJ. "Microbiological Control with Chlorine Dioxide Helps Save Energy," MP, 1977. 16(7), 24.
47. Ward WJ, Lee JW, Freymark, SG. "Advantages of Chlorine Dioxide as a Biocide, " Ammonia Plant Saf. 1978.20, 64.
48. Pacheco AM, Durham HE, Dhillon R, Edward C. "The Use of Chlorine Dioxide to Control Microbiological Growth in an Ethylene Glycol Contaminated Cooling Tower... A Case History," CTI 1989 Mtg, TP89‐14.
49. Sapi E, Kaur, Anyanwu N, Luecke S, Datar, A, et al. Evaluation of in vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist 4:2011. 97–113.
50. www.attc.org - www.lgcstandards.com
51. Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline. Proc Natl Acad Sci USA. 2009. 106:18656–61. 10.1073/pnas.0908236106
52. Barbour AG. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 1984. 57:521-525.
54. Feng J, Wang T, Zhang S, Shi W, Zhang Y. An Optimized SYBR GREEN I/PI Assay for Rapid Viability Assessment and Antibiotic Susceptibility Testing for Borrelia burgdorferi. PLoS ONE 2014. 9(11): e111809.
55. ASTM International. Standard Guide for Assessment of Antimicrobial activity using a time kill procedure. ASTM Standard. Designation E2315-16. 2016.
57. Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology. 2000;146:119–27.
58. Zhang Y. Persisters, persistent infections and the Yin-Yang model. Emerg Microbes Infect. 2014;3:e3.
59. Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, Pabbati N, et al. Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLoS ONE. 2012;7:e48277.
60. Kurtti TJ, Munderloh UG, Johnson RC, Ahlstrand GG. Colony formation and morphology in Borrelia burgdorferi. J Clin Microbiol. 1987;25:2054–8.
61. Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W. Heterogeneity of Borrelia burgdorferi in the skin. Am J Dermatopathol. 1996;18:571–9.
62. Mursic VP, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants. Infection. 1996;24:218–26.
63. Brorson O, Brorson SH. Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes. Infection. 1997;25:240–6.
64. Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme borreliosis. J Neuroinflamm. 2008;5:40.
65. Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, et al. Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist. 2011;4:97–113.
70. Meriläinen L, Herranen A, Schwarzbach A, Gilbert L. Morphological and biochemical features of Borrelia burgdorferi pleomorphic form. Microbiology. 2015;161:516–27.
71. Murgia R, Cinco M. Induction of cystic forms by different stress conditions in Borrelia burgdorferi. APMIS. 2004;112:57–62.
72. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrob Agents Chemother. 1995;39:1127–33.
73. Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline. Proc Natl Acad Sci USA. 2009;106:18656–61.
74. Drecktrah D, Lybecker M, Popitsch N, Rescheneder P, Hall LS, Samuels DS. The Borrelia burgdorferi RelA/SpoT homolog and stringent response regulate survival in the tick vector and global gene expression during starvation. PLoS Pathog. 2015;11:e1005160.
75. Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology. 2000;146:119–27.
76. Brorson O, Brorson SH. Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes. Infection. 1997;25:240–6.
77. Murgia R, Cinco M. Induction of cystic forms by different stress conditions in Borrelia burgdorferi. APMIS. 2004;112:57–62.
78. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrob Agents Chemother. 1995;39:1127–33.
79. Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline. Proc Natl Acad Sci USA. 2009;106:18656–61.
80. Caskey JR, Embers ME. Persister development by Borrelia burgdorferi populations in vitro. Antimicrob Agents Chemother. 2015;59:6288–95.
81. Feng J, Wang T, Shi W, Zhang S, Sullivan D, Auwaerter PG, et al. Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. EMI. 2014;3:e49.
82. Gruntar I, Malovrh T, Murgia R, Cinco M. Conversion of Borrelia garinii cystic forms to motile spirochetes in vivo. APMIS. 2001;109:383–8.
83. Lewis K. Persister cells. Annu Rev Microbiol. 2010;64:357–72.
84. Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother. 2015;59:4616–24
85. Hobby GL, Meyer K, Chaffee E. Observations on the mechanism of action of penicillin. Exp Biol Med. 1942;50:281–5.
86. Bigger JW. Treatment of staphylococcal infections with penicillin by intermittent sterilization. Lancet. 1944;244:497–500.
87. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230:13–8
88. Brisson D., Drecktrah D., Eggers CH, Samuels, DS. Genetics of Borrelia burgdorferi. Annu Rev Genet. 2012; 46: 10.1146/annurev-genet-011112-112140.
89. Ozawa T, Kwan T. Electron spin resonance studies of chlorine dioxide (ClO2) in aqueous solutions. Chem Pharm Bull 1983; 31: 2864-7.
90. McCarthy JA. Bromide and chlorine as water disinfectants. J. New Engl Water Works Assoc 1944; 58: 55-68.
91. Fukuyama MY, Tan H, Wheeler WB, Wei C. Reaction of aqueous chlorine and chlorine dioxide with model food compounds. Environ Health Perspect 1986; 69: 267-74.
92. Ogata N, Shibata T. Protective effect of low-concentration chlorine dioxide gas against influenza A virus infection. J Gen Virol. 2008. 89: 60-67
93. Morino H, Fukuda T, Miura T, Lee C, Shibata T, Sanekata T. Inactivation of feline calicivirus, a norovirus surrogate, by chlorine dioxide gas. Biocontrol Sci. 2009. 14: 147-153.
94. Sanekata T, Fukuda T, Miura T, Morino H, Lee C, Maeda K, Araki K, Otake T, Kawahata T, Shibata T. Evaluation of the antiviral activity of chlorine dioxide and sodium hypochlorite against feline calicivirus, human influenza virus, measles virus, canine distemper virus, human herpesvirus, human adenovirus, canine adenovirus and canine parvovirus. Biocontrol Sci. 2010. 15: 45-49.
95. Ma JW, Huang BS, Hsu CW, Peng CW, Cheng ML, Kao JY, Way TD, Yin HC, Wang SS. Efficacy and safety evaluation of a chlorine dioxide solution. Int J Environ Res Public Health. 2017. 14: E329.
96. Ofori I, Maddila S, Lin J, Jonnalagadda SB. Chlorine dioxide oxidation of Escherichia coli in water - A study of the disinfection kinetics and mechanism. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2017. 52: 598-606
97. Simpson GD, Miller RF, Laxton GD, Clements WR (1993) A focus on chlorine dioxide: the "ideal" biocide. Corrosion 93. New Orleans, La, March 8-12. paper No. 472.
98. Alvarez ME, O’Brien RT. Mechanism of inactivation of poliovirus by chlorine dioxide and iodine. Appl Environ Microbiol 1982; 44: 1064-71.
99. Tachikawa M, Saita K, Tezuka M, Sawamura R. Inactivation of poliovirus with chlorine dioxide. Jpn J Toxicol Environ Health 1993; 39: 572-6.
100. Wang XW, Li JS, Jin M, et al. Study on the resistance of severe acute respiratory syndrome-associated coronavirus. J Virol Methods 2005; 126: 171-7.
101. Li JW, Xin ZT, Wang XW, Zheng JL, Chao FH. Mechanisms of inactivation of hepatitis A virus in water by chlorine dioxide. Water Res 2004; 38, 1514-9.
102. Chen YS, Vaughn JM. Inactivation of human and simian rotaviruses by chlorine dioxide. Appl Environ Microbiol 1990; 56: 1363-6.
103. Kawada, Hiroshi, Haneda, Tadayoshi, Soil Disinfection by Using Aqueous Chlorine Dioxide Solutions, Patent application: JP95-111095 13 Apr 1995.
104. Report from Cornell, available from Frontier Pharmaceutical, Inc. upon request.
105. Scatina, J, Abdel-Rahman, M. The Inhibitory Effect of Alcide, an Antimicrobial Drug, on Protein Synthesis in E. Coli, J Appl. Tox., 1985, 5, 6.
106. Suh, DH, Abdel-Rahman, MS, Bull, RJ. Effect of Chlorine Dioxide and Its Metabolites in Drinking Water of Fetal Development in Rats, J. Appl. Toxicol. 1983, 3, 75-79.
107. Tuthill, RW, Guisti, RA, Moore, GS, Calabrese, FJ. Health Effects Among Newborns After Prenatal Exposure to ClO2 Disinfected Drinking Water, Envir. Health Perspect, 1982, 46, 39-45,
108. Gerges, AR, Skowronski, Effects of Alcide Gel on Fetal Development on Rats and Mice, J. of Applied Tox., 1985, 5, No. 2
109. Haag, HB. The Effects on Rats of Chromic Administration of Sodium Chlorite and Chlorine Dioxide in Drinking Water, Med. Col. Virginia, Dept. Phys, & Pharm., Report to Olin Corp., February 7, 1949
110. Lockett, J., Oxodene: Longevity of Honey Bees, Journal of Econ. Entomology, vol. 65, No. 1, Feb. 1972
111. Tick-Borne Zoonoses in the United States: Persistent and Emerging Threats to Human Health Rebecca J. Eisen, PhD, Kiersten J. Kugeler, PhD, Lars Eisen, PhD, Charles B. Beard, PhD, Christopher D. Paddock, MD. ILAR J. 2017 December 15; 58(3): 319–335. doi:10.1093/ilar/ilx005.